08:00 , Nov 12, 2007 |  BC Week In Review  |  Company News

Spectral Diagnostics, Toray Medical Co. Ltd. sales and marketing update

Toray received exclusive rights to distribute SDI's Endotoxin Activity Assay (EAA) in Japan. In 2006, the companies partnered to combine the severe sepsis risk test with Toray's Toraymyxin endotoxin removal device (see BioCentury, June 12,...
07:00 , Sep 24, 2007 |  BC Week In Review  |  Company News

Menarini, Spectral Diagnostic Inc. sales and marketing update

SDI launched its Endotoxin Activity Assay (EAA) , a sepsis diagnostic, in Germany. SDI will sell the diagnostic through its marketing partner, Menarini's A. Menarini Diagnostics Deutschland division. Menarini Group , Florence, Italy   Spectral...
07:00 , May 21, 2007 |  BC Week In Review  |  Company News

Spectral Diagnostics, Estor S.p.A. sales and marketing update

Estor will distribute SDI's Endotoxin Activity Assay (EAA) to hospitals in Italy to test for severe sepsis risk. Spectral Diagnostics Inc. (TSX:SDI), Toronto, Ontario   Estor S.p.A. , Milan, Italy   Business: Diagnostic  ...
07:00 , Jun 12, 2006 |  BC Week In Review  |  Company News

Spectral Diagnostics, Toray Medical Co. Ltd. deal

The companies partnered to combine SDI's Endotoxin Activity Assay (EAA) , a severe sepsis risk test, with Toray's Toraymyxin endotoxin removal device. Further terms were not disclosed. Spectral Diagnostics Inc. (TSX:SDI), Toronto, Ontario   Toray...
08:00 , Mar 29, 2004 |  BC Week In Review  |  Company News

Spectral Diagnostics, Cardinal Health sales and marketing update

The companies expanded their 2003 deal for CAH to exclusively distribute in the U.S. SDI's Cardiac STATus point-of-care tests, which measure markers for myocardial infarction (MI). As expanded, CAH also will distribute SDI's Endotoxin Activity...
08:00 , Nov 10, 2003 |  BC Week In Review  |  Company News

Spectral Diagnostics sales and marketing update

SDI launched its Endotoxin Activity Assay (EAA) severe sepsis risk test in Canada. Spectral Diagnostics Inc. (TSE:SDI), Toronto, Ontario   Business: Diagnostic  ...
07:00 , Sep 15, 2003 |  BC Week In Review  |  Clinical News

Endotoxin Activity Assay regulatory update

The EMEA granted EU marketing clearance for SDI's EAA severe sepsis risk test. The product already is approved in the U.S. Spectral Diagnostics Inc. (TSE:SDI), Toronto, Ontario   Product: Endotoxin Activity Assay (EAA)   Business:...
07:00 , Jul 21, 2003 |  BC Week In Review  |  Company News

Elan, Spectral Diagnostics deal

The companies ended their 1998 deal to develop and commercialize sepsis assays including SDI's Endotoxin Activity Assay (EAA) , which is marketed to identify patients at risk for developing severe sepsis upon admission to the...
07:00 , Jul 18, 2003 |  BC Extra  |  Company News

Spectral, Elan end assay deal

Spectral Diagnostics (TSE:SDI) and ELN ended their 1998 deal to develop and commercialize sepsis assays, including SDI's Endotoxin Activity Assay (EAA) , which is approved to identify patients at risk for developing severe sepsis upon...
07:00 , Jun 23, 2003 |  BC Week In Review  |  Clinical News

Endotoxin Activity Assay regulatory update

The FDA granted final marketing clearance for SDI's EAA severe sepsis risk test. Earlier this year, FDA said the test qualified for marketing clearance under the de novo process, which is a regulatory provision for...